Ticagrelor or Prasugrel in ST Elevation MI

In patients undergoing ST elevation acute myocardial infarction (STEMI) receiving primary PCI, no significative differences between prasugrel and ticagrelor were found. However, the latter was associated to a significantly higher number of repeat MI when considered separately. 

ticagrelor vs. aspirina

Few studies have compared the efficacy and safety of the two most potent oral P2Y12 receptor inhibitors in STEMI patients undergoing PCI. There is a large body of evidence resulting from studies comparing each of them separately vs clopidogrel, but not against each other. 

This analysis prespecified in the ISAR REACT-5 protocol included 1653 STEMI patients randomized to ticagrelor or prasugrel.

The primary end point was a composite of death, MI and stroke at one year after randomization. The secondary end point was the incidence of major bleeding (BARC 3 to 5) for the same period. 

The combined end point occurred in 10.1% of patients in the ticagrelor group vs 7.9% of prasugrel patients (p=0.10). When considering its separate components, they observed similar results in death (4.9% vs 4.7%, p=0.83) and stroke (1.3% vs 1%, p=0.46), as well as definite thrombosis (1.8% vs 1%, p=0.15). 


Read also: TCT 2020 | Ticagrelor Monotherapy After ST-Segment Elevation Infarction.


The difference in new events rate was significant, prasugrel winning with 2.8% against 5.3% of ticagrelor (p=0.010). This difference tends to disappear with all events combined. 

Major bleeding rates according to the Bleeding Academic Research Consortium (BARC 3 to 5) were practically identical with 6.1% for ticagrelor and 5.1% for prasugrel (p=0.36).

Conclusion

In STEMI patients undergoing primary PCI there were no differences in the combined primary end point between ticagrelor and prasugrel. When considering MI separately, prasugrel has an advantage. 

Original Title: Ticagrelor or Prasugrel in Patients with ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Reference: Alp Aytekin et al. Circulation. 2020, Online ahead of print. doi: 10.1161/CIRCULATIONAHA.120.050244.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....